A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

Annals of the Rheumatic Diseases

Volumn 74, Issue 9, 2015, Pages 1667-1675

  Furie, R A ^a   Leon, G ^b   Thomas, M ^c   Petri, M A ^d   Chu, A D ^e   Hislop, C ^e   Martin, Renee S ^e   Scheinberg, M A ^f  

^a North Shore Long Island Jewish Health System ^*  (United States)

^b Rheumatology Gynecology and Reproduction Institute   (Peru)

^c Azienda Ospedaliera della provincia di Pavia   (India)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Anthera Pharmaceuticals Inc   (United States)

^f Rheumatology Department   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BLISIBIMOD; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CREATININE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; AMG623 PEPTIBODY; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; HYBRID PROTEIN; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROENTERITIS; GIANT CELL TUMOR; HEADACHE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENINGITIS; METATARSALGIA; NEUTROPHIL COUNT; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SEPTIC SHOCK; SIDE EFFECT; SINUSITIS; SKIN ABSCESS; SKIN PAPILLOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS MYOMA; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, ANTINUCLEAR; ANTIMALARIALS; COMPLEMENT C3; COMPLEMENT C4; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84942111128     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-205144     Document Type: Article

References (27)

1. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006;15:308-18.
2. Siegel M, Lee SL. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum 1973;3:1-54.
3. Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 2005;204:43-54.
4. Hsu H, Khare SD, Lee F, et al. A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. Clin Exp Rheumatol 2012;30:197-201.
5. Stohl W, Merrill JT, Looney RJ, et al. Phase 1a Single- and Phase 1b Multiple-Dose Studies of AMG 623 (an anti-BAFF peptibody) in Systemic Lupus Erythematosus (SLE). Arthritis Rheum 2008;58:S565.
6. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9.
7. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebocontrolled, phase 3 trial. Lancet 2011;377:721-31.
8. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
9. Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8.
10. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9.
11. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
12. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-62.
13. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
14. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999;42:1785-96.
15. Petri M, Kim MY, Kalunian KC, et al. Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. N Engl J Med 2005;353:2550-8.
16. Van Vollenhoven R, Schwarting A, Navarra S, et al. Durability of response in SLE patients treated with belimumab in the Phase 3 BLISS-52 and BLISS-76 studies. Ann Rheum Dis 2011;70(Suppl3):321.
17. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
18. Solorzano GT, Silva MV, Moreira SR, et al. Urinary protein/creatinine ratio versus 24-hour proteinuria in the evaluation of lupus nephritis. J Bras Nefrol 2012;34:64-7.
19. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004;50:3418-26.
20. Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22:63-72.
21. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328-37.
22. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-9.
23. Lefkowith JB, Kiehl M, Rubenstein J, et al. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. J Clin Invest 1996;98:1373-80.
24. Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534-45.
25. Satoskar AA, Brodsky SV, Nadasdy G, et al. Discrepancies in glomerular and tubulointerstitial/vascular immune complex IgG subclasses in lupus nephritis. Lupus 2011;20:1396-403.
26. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus. Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting. Arthritis Rheum 2004;50: 3427-31.
27. Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074-82.